BNGO
Bionano Genomics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.20
−3.23%Year over year
Reported trailing growth
- Revenue
- +10.0%
- EBITDA
- +63.3%
- EBIT
- +55.4%
- EPS
- +91.7%
- Free cash flow
- +21.4%
- Operating cash flow
- +21.4%
Forward estimates
Based on analyst estimates
- Revenue
- +20.0%
- EBITDA
- +76.4%
- EPS
- +77.5%
Three-year CAGR
- Revenue
- +0.8%
- EBITDA
- +83.3%
- EBIT
- +67.9%
- Net income
- +76.4%
- EPS
- +94.5%
- Free cash flow
- +76.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026